CONVECTIVE VOLUME, PATIENT ANTHROPOMETRIC CHARACTERISTICS AND RISK OF ALL-CAUSE MORTALITY IN HEMODIAFILTRATION: A COHORT STUDY

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/304f968f5cb98e42446b21dd8e78161e.pdf
CONVECTIVE VOLUME, PATIENT ANTHROPOMETRIC CHARACTERISTICS AND RISK OF ALL-CAUSE MORTALITY IN HEMODIAFILTRATION: A COHORT STUDY

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Krister
Cromm
Krister Cromm krister.cromm@freseniusmedicalcare.com Fresenius Medical Care Global Medical Office Bad Homburg Germany * Charite Center for Patient-Centered Outcomes Research Berlin Germany
Robin W. Vernooij r.w.m.vernooij-2@umcutrecht.nl Utrecht University Universitair Medisch Centrum Utrecht Utrecht Netherlands -
Bernaud J. Canaud canaudbernard@gmail.com University of Montpellier Montpellier France -
Claudia M. Barth claudia.barth@bbraun.com B Braun Avitum AG Melsungen Germany -
Jörgen B. Hegbrant jbahegbrant@gmail.com Lund University Lund Sweden -
Andrew Davenport andrewdavenport@nhs.net University College London London United Kingdom -
Mark Woodward markw@georgeinstitute.org.au The George Institute for Global Health UK Oxford United Kingdom - The George Institute for Global Health Australia Sydney Australia
Michiel L. Bots M.L.Bots@umcutrecht.nl Utrecht University Universitair Medisch Centrum Utrecht Utrecht Netherlands -
Peter J. Blankestijn P.J.Blankestijn@umcutrecht.nl Utrecht University Universitair Medisch Centrum Utrecht Utrecht Netherlands -
Giovanni Strippoli gfmstrippoli@gmail.com University of Bari Department of Precision and Regenerative Medicine and Ionian Area (Dimepre-J) Bari Italy - University of Sydney School of Public Health Sydney Australia
-
-
-
-
-

Higher ultrafiltration volumes in hemodiafiltration (HDF), a surrogate for convective dose, have been associated with improved survival. Whether this advantage is affected by patients' anthropometric characteristics (body mass index (BMI) or body surface area (BSA)) is unclear.


We analyzed individual patient data from 5 randomized trials to evaluate the association between convective volume and risk of all-cause mortality stratified by BMI and BSA. Cox proportional hazards models with interaction terms, Kaplan-Meier survival curves and multivariable spline models were used to explore potential nonlinear and joint effects.

Our cohort consisted of 2083 patients treated with HDF. Convective volume, BMI, and BSA were each categorized into tertiles (for volumes: 17.9 L (low), 22.8 L (medium), and 27.7 L (high); for BMI 20.9 kg/m (low), 25.2 kg/m (medium), and 31.7 kg/m (high); for BSA 1.57 m (low), 1.79 m (medium), and 2.03 m (high)). Higher convective volume was significantly associated with reduced all-cause mortality (HR 0.62, 95% CI: 0.49–0.78 for highest vs lowest tertile). In joint analyses, patients with medium or high BMI or BSA receiving high convective volume had the lowest mortality risks (HR: 0.53, 95% CI: 0.36–0.78). In contrast, the interaction between BSA and convection volume was less consistent and did not show a clear gradient (see Figures).

In patients receiving HDF, high ultrafiltration volumes were associated with significantly lower risk of all-cause mortality, particularly among those with medium to high BMI. This relationship was not consistently observed with BSA. It is plausible that BMI and BSA capture different physiological characteristics. BMI may reflect nutritional status or body composition, while BSA may be a proxy for uremic solute distribution volume. Ultrafiltration volume requirements may align more closely with BMI than BSA, indicating that BMI could be a more practical metric for personalizing convective volume in HDF to optimize patient outcomes.

Kewords